DK3126521T3 - HNF4G-RSPO2-fusionsgen - Google Patents

HNF4G-RSPO2-fusionsgen Download PDF

Info

Publication number
DK3126521T3
DK3126521T3 DK15772589.6T DK15772589T DK3126521T3 DK 3126521 T3 DK3126521 T3 DK 3126521T3 DK 15772589 T DK15772589 T DK 15772589T DK 3126521 T3 DK3126521 T3 DK 3126521T3
Authority
DK
Denmark
Prior art keywords
hnf4g
rspo2 fusion
rspo2
fusion
Prior art date
Application number
DK15772589.6T
Other languages
English (en)
Inventor
Jie Cai
Henry Li
Original Assignee
Crown Bioscience Inc Taicang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Bioscience Inc Taicang filed Critical Crown Bioscience Inc Taicang
Application granted granted Critical
Publication of DK3126521T3 publication Critical patent/DK3126521T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK15772589.6T 2014-04-04 2015-04-03 HNF4G-RSPO2-fusionsgen DK3126521T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410135569 2014-04-04
PCT/CN2015/075882 WO2015149720A1 (en) 2014-04-04 2015-04-03 Hnf4g-rspo2 fusion gene and use thereof in treatment of cancer

Publications (1)

Publication Number Publication Date
DK3126521T3 true DK3126521T3 (da) 2019-06-17

Family

ID=54239415

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15772589.6T DK3126521T3 (da) 2014-04-04 2015-04-03 HNF4G-RSPO2-fusionsgen
DK15773840.2T DK3126528T3 (da) 2014-04-04 2015-04-03 Fremgangsmåder til bestemmelse af modtagelighed over for MEK/ERK-inhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15773840.2T DK3126528T3 (da) 2014-04-04 2015-04-03 Fremgangsmåder til bestemmelse af modtagelighed over for MEK/ERK-inhibitorer

Country Status (7)

Country Link
US (3) US10683550B2 (da)
EP (3) EP3126521B1 (da)
CN (3) CN106536753B (da)
DK (2) DK3126521T3 (da)
ES (2) ES2896404T3 (da)
PT (2) PT3126528T (da)
WO (2) WO2015149721A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018025971A1 (ja) * 2016-08-04 2018-02-08 静岡県 がんの発症リスクの有無を判定する方法
WO2018058490A1 (zh) * 2016-09-30 2018-04-05 武汉华大吉诺因生物科技有限公司 Col14a1衍生的肿瘤抗原多肽及其应用
EP3906031A4 (en) * 2019-01-02 2022-10-05 Zhejiang Crownmab Biotech Co. Ltd. CANCER TREATMENT USING A MULTI-TARGETED KINAS INHIBITOR IN COMBINATION WITH PROTEIN KINASES BIOMARKERS
CN111434353A (zh) * 2019-02-02 2020-07-21 中国科学院上海营养与健康研究所 Ras抑制剂筛选及疗效标志物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
DE69032864T3 (de) 1989-03-29 2013-01-31 The Johns Hopkins University Nachweis des Ausfalls des Wildtyps des p53-Gens
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CN1202932A (zh) 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
WO1997019110A1 (en) 1995-11-23 1997-05-29 Cancer Research Campaign Technology Limited Materials and methods relating to the identification and sequencing of the brca2 cancer susceptibility gene and uses thereof
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ES2191187T3 (es) 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
EP0984930B1 (en) 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
WO1999010349A1 (en) 1997-08-22 1999-03-04 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
CA2309690A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
EA005032B1 (ru) 1998-05-29 2004-10-28 Сьюджен, Инк. Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
DK2050749T3 (da) 2006-08-08 2018-01-08 Chugai Pharmaceutical Co Ltd Pyrimidinderivat som pi3k-inhibitor og anvendelse deraf
KR20090071603A (ko) 2006-09-19 2009-07-01 노파르티스 아게 Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커
TW200938201A (en) 2008-02-07 2009-09-16 Chugai Pharmaceutical Co Ltd Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
CN101524529B (zh) * 2008-03-04 2011-09-28 中国人民解放军第二军医大学 HNF4α诱导分化治疗人体恶性实体瘤
CN102439174B (zh) * 2009-02-19 2015-02-04 康奈尔大学 基于检测slc45a3-elk4融合转录子的用于诊断前列腺癌的组合物和方法
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
US8945556B2 (en) * 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
CA2818544A1 (en) * 2010-11-19 2012-05-24 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment with braf inhibitor
US20140024539A1 (en) 2011-02-02 2014-01-23 Translational Genomics Research Institute Biomarkers and methods of use thereof
CN103571848B (zh) * 2012-08-10 2016-06-29 安徽医科大学第一附属医院 点状掌跖角化病的致病基因及其用途

Also Published As

Publication number Publication date
CN111808957A (zh) 2020-10-23
PT3126528T (pt) 2021-09-09
CN106536753A (zh) 2017-03-22
US20180282814A1 (en) 2018-10-04
CN106460060B (zh) 2020-02-11
ES2896404T3 (es) 2022-02-24
EP3126521A4 (en) 2017-11-08
WO2015149720A1 (en) 2015-10-08
US10501805B2 (en) 2019-12-10
CN106460060A (zh) 2017-02-22
DK3126528T3 (da) 2021-11-08
EP4012049A2 (en) 2022-06-15
EP3126521B1 (en) 2019-03-20
EP4012049A3 (en) 2022-08-24
WO2015149721A1 (en) 2015-10-08
EP3126528B1 (en) 2021-08-18
PT3126521T (pt) 2019-06-27
EP3126528A1 (en) 2017-02-08
CN106536753B (zh) 2020-07-21
US20200123622A1 (en) 2020-04-23
EP3126528A4 (en) 2018-02-21
US20170114414A1 (en) 2017-04-27
ES2727374T3 (es) 2019-10-15
EP3126521A1 (en) 2017-02-08
US10683550B2 (en) 2020-06-16

Similar Documents

Publication Publication Date Title
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3006072T3 (da) Karadgang
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3222714T3 (da) Phytasemutanter
DK3119396T3 (da) Muscarinreceptoragonister
DK3107562T3 (da) P97-ids-fusionsproteiner
DK4242916T3 (da) Forstøver
DK3183340T3 (da) Termolabile exonukleaser
EP4011484C0 (en) CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DE112015001664A5 (de) Betätigungsaktuator
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DE112015005041A5 (de) Gargerätevorrichtung
DK3110439T3 (da) Pcsk9-vacciner
DE102014000623A8 (de) Halbhohlnietelement
DK3126521T3 (da) HNF4G-RSPO2-fusionsgen
DK3009858T3 (da) Skyradar
FI20145913A (fi) Staattorimekanismi
DE202014005655U8 (de) llluminationsvorrichtung
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer
ES1133830Y (es) Columbario
DE112015005055A5 (de) Gargerätevorrichtung
DK3091875T3 (da) Vipbar taburet
ES1114205Y (es) Heliostato